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AbstrAct
Introduction Limited evidence from birth cohort studies 
suggests that lower prenatal iron status may be a risk 
factor for childhood respiratory and atopic outcomes, 
but these observational findings may be confounded. 
Mendelian randomisation (MR) can potentially provide 
unconfounded estimates of causal effects by using 
common genetic variants as instrumental variables. We 
aimed to study the relationship between prenatal iron 
status and respiratory and atopic outcomes in the offspring 
using MR.
Methods In the Avon Longitudinal Study of Parents 
and Children birth cohort, we constructed four maternal 
genotypic risk scores by summing the total number of risk 
alleles (associated with lower iron status) across single 
nucleotide polymorphisms known to be associated with 
at least one of four iron biomarkers (serum iron, ferritin, 
transferrin and transferrin saturation). We used MR to study 
their associations with respiratory and atopic outcomes in 
children aged 7–9 years (n=6002).
results When analyses were restricted to mothers 
without iron supplementation during late pregnancy, 
negative associations were found between the maternal 
transferrin saturation score and childhood forced 
expiratory volume in 1 s and forced vital capacity 
(difference in age, height and gender-adjusted SD units 
per SD increase in genotypic score: −0.05 (−0.09, −0.01) 
p=0.03, and −0.04 (−0.08, 0.00) p=0.04, respectively).
conclusion Using MR we have found weak evidence 
suggesting that low maternal iron status during pregnancy 
may cause impaired childhood lung function.
bAckground
Epidemiological studies have suggested that 
maternal nutrition during pregnancy may 
influence the development of childhood 
respiratory and atopic disorders,1 2 though 
evidence is conflicting and data are lacking 
on associations with outcomes beyond 
5 years of age. In the West, iron deficiency 
is common in pregnancy,3 but few studies 
have investigated the role of this potentially 
modifiable risk factor in the development 
of asthma and allergies. Prenatal iron defi-
ciency could plausibly influence respiratory 
and allergic outcomes by causing prematurity 
and impaired fetal growth. Gestational age at 
delivery and offspring birth weight are associ-
ated with maternal haemoglobin concentra-
tion4 and with childhood wheezing, asthma, 
eczema, allergic sensitisation and impaired 
lung function.5–8 
In the Avon Longitudinal Study of Parents 
and Children (ALSPAC), we reported an 
inverse association between umbilical cord 
iron concentration and wheezing and eczema 
in early childhood.9 Exploratory analyses 
in a small subgroup of another UK birth 
cohort—the SEATON study—suggested 
associations between different indicators of 
lower maternal iron status in early gestation 
and an increased risk of wheezing and lower 
lung function in the offspring at 10 years of 
age, although findings were inconsistent 
across the different indicators, and no asso-
ciations were found with asthma or eczema.10 
Key messages
 ► In the literature there have been clues on the 
role of maternal iron status and anaemia during 
pregnancy in the development of respiratory and 
atopic disorders during childhood. A concern 
with all observational studies, and particularly in 
nutritional epidemiology, is that findings may be 
influenced by confounding. In the present study, 
we used Mendelian randomisation, which is a 
form of instrumental variable analysis where a 
genetic variant can be used as a proxy for a specific 
exposure, to test whether maternal iron status 
during pregnancy is likely to be causally related to 
respiratory and atopic outcomes in the offspring.
 ► We have found weak evidence suggesting that low 
maternal iron status during pregnancy may cause 
impaired childhood lung function.
 ► Given that iron deficiency is common in pregnancy 
in the West, these findings might have public health 
implications and need to be further investigated. 
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Iron deficiency is the most common cause of anaemia 
in pregnancy,11 and recent analyses conducted in the 
ALSPAC birth cohort showed associations between lower 
maternal haemoglobin concentrations in pregnancy, 
and an increased risk of atopy, elevated IgE and reduced 
lung function in the offspring at 7 years of age.12 In the 
USA, a prospective study found positive associations for 
maternal anaemia with both early childhood wheezing 
and persistent wheezing,13 and a cross-sectional study in 
children reported positive associations between anaemia 
and atopic disease.14 On the other hand, a prospective 
study conducted in the Netherlands did not confirm any 
association between maternal haemoglobin concentra-
tions during pregnancy and wheezing in early childhood 
or asthma outcomes at the age of 6 years.15
A concern with all observational studies, and partic-
ularly in nutritional epidemiology, is that findings may 
be influenced by confounding. Mendelian randomisa-
tion (MR) is a form of instrumental variable (IV) anal-
ysis where a genetic variant can be used as a proxy for a 
specific exposure to test whether that exposure is likely 
to be causally related to an outcome.16 A key principle 
underpinning MR is that genotype is randomly allocated 
during meiosis, and consequently associations between 
genetic variants and disease are not generally susceptible 
to confounding by lifestyle factors. This approach was 
recently used in ALSPAC to determine whether maternal 
iron status in pregnancy was causally related to child’s 
IQ.17 The aim of this study was to use MR to determine 
whether maternal iron status during pregnancy is caus-
ally associated with respiratory and atopic outcomes in 
the offspring in the large population-based ALSPAC 
birth cohort.
Methods
Participants
The ALSPAC is a population-based birth cohort that 
recruited 14 541 predominantly white pregnant women 
resident in Avon, UK, with expected dates of delivery 
from 1 April 1991 to 31 December 1992. These preg-
nancies resulted in 13 613 singletons who were alive at 
1 year of age. The cohort has been followed since birth 
with annual questionnaires and, since age 7 years, with 
objective measures in annual research clinics. The study 
protocol has been described previously18 19 and further 
information can be found at http://www. alspac. bris. ac. 
uk, which contains details of all the data that are avail-
able: http://www. bris. ac. uk/ alspac/ researchers/ data- 
access/ data- dictionary/. 
outcome assessment
When the children were 7.5 years old, mothers were 
asked: ‘Has your child had any of the following in the 
past 12 months: wheezing with whistling; asthma; eczema; 
hay fever?’ Children were defined as having current 
doctor-diagnosed asthma at 7.5 years (primary outcome) 
if mothers responded positively to the question, ‘Has 
a doctor ever actually said that your study child has 
asthma?’ and positively to one or both of the questions 
on wheezing and asthma in the past 12 months. Atopy at 
7 years was defined by skin prick test as a positive reaction 
(maximum diameter of any detectable weal) to Dermato-
phagoides pteronyssinus, cat or grass (after subtracting posi-
tive saline reactions from histamine and allergen weals, 
and excluding children unreactive to 1% histamine). 
Serum total IgE (kU/L) was measured at 7 years by 
fluoroimmunoassay using the Pharmacia UNICAP system 
(Pharmacia and Upjohn Diagnostics, Uppsala, Sweden).
Lung function was measured by spirometry (Vitalo-
graph 2120) at age 8½ years after withholding short-
acting bronchodilators for at least 6 hours and long-acting 
bronchodilators and theophyllines for at least 24 hours. 
The best of three reproducible flow-volume curves was 
used to measure forced expiratory volume in 1 s (FEV1), 
forced vital capacity (FVC) and maximal mid-expira-
tory flow (FEF25-75). Lung function measurements were 
transformed to age, height and gender-adjusted SD 
units.20 The tests adhered to American Thoracic Society 
(ATS) criteria for standardisation and reproducibility of 
flow-volume measurement,21 with the exception of ATS 
recommendations for duration of expiration, since many 
young children cannot sustain exhalation for 6 s to estab-
lish FVC.22 We therefore used no volume change over >1 s 
to define the plateau phase of the flow-volume curve as 
the end-of-test criterion in those unable to blow >6 s.
genetic data and weighted genotypic risk score calculation
Maternal DNA was a mixture of samples extracted from 
blood samples collected during pregnancy and samples 
extracted from lymphoblastoid cell lines. ALSPAC 
mothers were genotyped using the Illumina human660W-
quad array at Centre National de Génotypage and geno-
types were called with Illumina GenomeStudio. PLINK 
(V.1.07) was used to carry out quality control measures 
on an initial set of 10 015 subjects and 557 124 directly 
genotyped single nucleotide polymorphisms (SNP). 
After applying rigorous quality control measures, geno-
type data were available for 8196 unrelated mothers (see 
online supplementary file for further details of genotype 
quality control and imputation methods). These data 
have been used in previous genome-wide association 
(GWA) studies.23 For details on child genotyping, see 
online supplementary file.
We identified 12 SNPs for analysis, recently shown 
in the largest GWA meta-analysis of iron biomarkers 
(Genetics of Iron Status (GIS) consortium) to be associ-
ated (p<5×10−8) with at least one of four iron biomarkers 
(serum iron, ferritin, transferrin and transferrin satura-
tion)24 (see table 1 for further details). Of these SNPs, 
five were genotyped and seven were imputed; imputa-
tion quality score was high (>0.97) for all SNPs. Pairwise 
linkage disequilibrium between the 12 selected SNPs 
was checked (single nucleotide polymorphisms anno-
tator, SNiPA25). In order to increase statistical power, we 
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constructed a weighted maternal genotypic risk score26 27 
for each iron biomarker, comprising the number of risk 
alleles—defined as those associated with lower iron status 
(hence the higher the score, the greater the risk of lower 
iron status)—multiplied by the genome-wide associa-
tion study (GWAS) effect estimates for each SNP-iron 
biomarker (serum iron, ferritin, transferrin and trans-
ferrin saturation) association,24 then summed over all 
SNPs, as summarised in table 1. As serum iron and other 
iron biomarkers had not been measured in ALSPAC 
mothers in pregnancy, we used maternal haemoglobin 
concentrations in pregnancy as proxy measures of 
maternal iron status in order to partially validate our IVs 
in the ALSPAC pregnant women.
Maternal and offspring characteristics
Data were available on selected characteristics known 
(from existing literature) to be associated with one 
or more of the outcomes of interest.28 These included 
maternal age at delivery, sex of child, season of birth, 
maternal history of atopic diseases (hay fever, asthma, 
eczema, allergies, or attacks of wheezing with whistling on 
the chest or attacks of breathlessness in the past 2 years), 
parity, highest educational qualification, housing tenure, 
financial difficulties, gestational age at delivery, birth 
weight, maternal pre-pregnancy body mass index and 
maternal factors during pregnancy (smoking status, 
anxiety score, paracetamol use, antibiotic use, infec-
tions, total energy intake and use of iron supplementa-
tion in early (<18 weeks) and late (20–32 weeks) preg-
nancy). Smoking status was categorised as the maximum 
exposure during pregnancy (never, passive smoking only, 
1–9 cigarettes per day, 10–19 cigarettes per day, ≥20 ciga-
rettes per day).
Measurement of haemoglobin
Maternal blood haemoglobin measurements (g/dL) were 
taken as part of routine antenatal care and abstracted 
from the women’s obstetric records by six trained 
research midwives. We derived the first haemoglobin as 
the haemoglobin measurement with the earliest gesta-
tional age for each woman, provided that this was before 
18 weeks’ gestation. If there was not a measurement 
prior to 18 weeks’ gestation, this variable was treated as 
missing. We derived the last haemoglobin as the haemo-
globin measurement with the latest gestational age for 
each woman, provided that this was after 28 weeks’ gesta-
tion, otherwise this variable was set to missing.
statistical analysis
Multiple births were excluded from the analyses. 
Although the ALSPAC population is largely white, moth-
er-child pairs were excluded from all analyses if the 
mother’s reported ethnicity was non-white or unknown. 
To address possible residual confounding by population 
substructure, we controlled for 10 variables derived by 
principal component analysis (PCA) from ALSPAC GWAS 
data.29 The distributions of maternal and offspring char-
acteristics were compared across maternal genotypic risk 
score quartiles using F statistics for differences in contin-
uous variables, and Χ2 tests for differences in categorical 
Table 1 SNPs associated with iron and iron biomarkers in a published genome-wide association meta-analysis24
SNPs Risk allele* Nearest gene(s)
Effect estimates reported†
Iron Ferritin Transferrin Transferrin saturation
rs1799945‡ C HFE −0.189 −0.065 0.114 −0.231
rs1800562§ G HFE −0.328 −0.204 0.479 −0.577
rs855791§ A TMPRSS6 −0.181 −0.055 0.044 −0.190
rs8177240† T/G¶ TF −0.066 0.380 −0.100
rs7385804‡ C TFR2 −0.064 −0.054
rs744653§ T WDR75–SLC40A1 −0.089 0.068
rs651007‡ T ABO −0.050
rs411988‡ A TEX14 −0.044
rs9990333§ C TFRC 0.051
rs4921915‡ A NAT2 0.079
rs6486121§ C ARNTL 0.046
rs174577‡ A FADS2 0.062
*Associated with lower iron status, lower ferritin status, higher transferrin status or lower transferrin saturation status with p<5.10−8.
†From meta-analysis of covariate-adjusted standardised regression coefficients of phenotypic values on the allele count for the risk allele.
‡Imputed SNP.
§Genotyped SNP.
¶T is the risk allele for iron (associated with lower iron status) and G is the risk allele for transferrin and transferrin saturation (associated with 
higher transferrin status and lower transferrin saturation status).
SNP, single nucleotide polymorphism. 
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variables. The main analyses were further adjusted for 
any maternal or offspring characteristic which was found 
to be associated with maternal genotypic risk scores. 
Logistic and linear regression was used to analyse asso-
ciations for individual SNPs (per risk allele effects) and 
maternal genotypic risk scores (per SD increase effects) 
with binary and continuous outcomes, respectively. After 
log-transforming total IgE, linear regression was used to 
estimate geometric mean ratios for IgE; confidence limits 
were calculated using Huber variances. Assumptions of 
Hardy-Weinberg equilibrium were formally tested using 
a likelihood ratio test and the asymptotic p value is 
reported.
Figure 1 shows a directed acyclic graph to illustrate 
potential confounders of the associations between 
maternal iron status in pregnancy and offspring respi-
ratory and atopic outcomes assessed using MR. As many 
of the ALSPAC women were supplemented with iron 
because of iron deficiency anaemia, especially in late 
pregnancy, and this could potentially affect the reliability 
of the IV as a predictor of maternal iron status, and dilute 
associations with childhood outcomes (see figure 1), 
we conducted sensitivity analyses stratifying our study 
population by iron supplementation in late pregnancy. 
However, if the probability of an individual choosing to 
take iron supplements depends on their current iron 
status, then stratification on supplementation status could 
introduce collider bias.30 This could lead to associations 
between the genetic score and outcome variables within 
the strata, even if there is no causal effect of iron status on 
the outcome. Therefore, a simulation study using param-
eters derived from the substantive analysis in the paper 
was conducted to assess the likely type 1 error rate for 
detecting a causal effect at different degrees of differen-
tial supplementation (see online supplementary file for 
further details). To address the issue of potential overlap 
between maternal and offspring genetic variants, and 
assess the extent to which this might have confounded 
the associations between the maternal genotypic scores 
and childhood outcomes, we studied the associations 
between the child’s genotypic scores and childhood 
outcomes. We also conducted MR-Egger and weighted 
median sensitivity analyses to assess potential pleiotropy 
and the likelihood of a causal effect.31 All statistical anal-
yses were carried out using Stata V.12.1 (StataCorp LP, 
USA).
results
Of the 13 613 singletons alive at 1 year of age, informa-
tion on maternal genotype was available for 8079, of 
whom 681 were excluded because of mother’s reported 
ethnicity (non-white/unknown). Of the remainder, 
there was information on at least one of the outcomes 
of interest for 6002 children (online supplementary 
figure 1).
Figure 1 Directed acyclic graph showing potential confounders of the association between maternal total iron status 
in pregnancy (exposure of interest) and offspring respiratory and atopic outcomes (outcomes of interest) assessed using 
Mendelian randomisation. BMI, body mass index.
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No linkage disequilibrium was detected among the 12 
SNPs (all pairwise correlations between the 12 variants 
had an R²<0.10). No strong evidence of Hardy-Weinberg 
disequilibrium was found among the 12 SNPs (online 
supplementary table 1). The maternal genotypic iron, 
ferritin, transferrin and transferrin saturation scores were 
based on five SNPs, six SNPs, nine SNPs and five SNPs, 
respectively (see table 1 for list of included SNPs). There 
was strong evidence (p trend <5.10−4) to suggest that 
three of the SNPs which were included in all four scores 
(rs1799945—nearest gene: HFE, rs1800562—nearest 
gene: HFE and rs855791—nearest gene: TMPRSS6), and 
the four maternal genotypic risk scores, were negatively 
associated with maternal haemoglobin concentrations in 
early and late pregnancy (table 2). When we stratified by 
iron supplementation in late pregnancy, although nega-
tive associations were found in both strata between the 
four genotypic scores and maternal haemoglobin in late 
pregnancy, stronger associations were mostly observed 
among unsupplemented women (table 3).
With increasing maternal genotypic iron score (most 
predictive of low iron status), usage of iron supple-
ments increased, especially during late pregnancy. The 
iron score was not associated with any other maternal 
or offspring characteristics (online supplementary 
table 2). Similar findings were obtained when maternal 
and offspring characteristics were studied according to 
the other maternal genotypic scores (data not shown). 
After controlling for iron supplementation in preg-
nancy and population substructure, no association was 
found between the maternal genotypic iron, transferrin 
and transferrin saturation scores and childhood atopic 
outcomes (table 4 and online supplementary table 3). 
Similar findings were obtained when the study popula-
tion was restricted to unsupplemented mothers (table 5 
and online supplementary table 4).
Overall, there was no evidence for associations between 
the genotypic scores and childhood lung function 
(table 4); however, when restricted to unsupplemented 
mothers, negative associations were found between the 
transferrin saturation score and childhood FEV1 and 
FVC. There was also weak evidence for negative associa-
tions between the iron and transferrin scores and child-
hood FEV1 and FVC (table 5). No association with any 
outcome was observed among supplemented women 
(data not shown).
As a post hoc analysis, the individual SNP associations 
with the four iron biomarkers (based on GWA data24) 
were plotted against the individual maternal SNP associa-
tions with childhood FEV1 (online supplementary figure 
2) and childhood FVC (online supplementary figure 3). 
These plots suggested that the weak associations between 
the maternal genotypic scores and FEV1 and FVC in the 
offspring of unsupplemented women were partly driven 
by rs1800562 (nearest gene: HFE). The simulation study 
conducted to assess the impact of collider bias on our 
Table 2 Associations between maternal genotype at individual iron-related SNPs, maternal genotypic risk scores and 
haemoglobin concentrations in early and late pregnancy in ALSPAC
SNPs Risk allele*
Early pregnancy (n=5219) Late pregnancy (n=5438)
β† (95% CI) P trend β† (95% CI) P trend
rs1799945 C −0.07 (−0.12 to –0.02) 0.005 −0.09 (−0.14 to –0.04) 2.3×10−4
rs1800562 G −0.13 (−0.20 to –0.06) 1.5×10−4 −0.19 (−0.26 to –0.13) 1.1×10−8
rs855791 A −0.11 (−0.15 to –0.08) 1.8×10−10 −0.12 (−0.15 to –0.08) 1.3×10−11
rs8177240 T/G‡ 0.02 (−0.02 to 0.05) 0.34 −0.02 (−0.06 to 0.01) 0.23
rs7385804 C 0.01 (−0.03 to 0.04) 0.77 0.00 (−0.03 to 0.04) 0.79
rs744653 T −0.04 (−0.09 to 0.01) 0.10 0.00 (−0.04 to 0.05) 0.88
rs651007 T −0.04 (−0.08 to 0.00) 0.07 −0.05 (−0.09 to –0.01) 0.02
rs411988 A −0.02 (−0.06 to 0.01) 0.17 0.00 (−0.03 to 0.03) 0.99
rs9990333 C 0.01 (−0.03 to 0.04) 0.71 0.01 (−0.03 to 0.04) 0.69
rs4921915 A −0.03 (−0.07 to 0.01) 0.15 −0.02 (−0.06 to 0.02) 0.43
rs6486121 C 0.00 (−0.03 to 0.04) 0.96 0.01 (−0.03 to 0.04) 0.62
rs174577 A 0.00 (−0.03 to 0.04) 0.79 −0.01 (−0.05 to 0.03) 0.57
Iron score −0.09 (−0.11 to –0.06) 2.3×10−12 −0.11 (−0.13 to –0.08) 1.8×10−18
Ferritin score −0.09 (−0.12 to –0.07) 6.1×10−13 −0.09 (−0.12 to –0.07) 8.2×10−14
Transferrin score −0.05 (−0.07 to –0.03) 4.8×10−5 −0.04 (−0.07 to –0.02) 7.6×10−4
Transferrin saturation score −0.09 (−0.11 to –0.06) 9.8×10−13 −0.11 (−0.12 to –0.08) 5.5×10−16
*Associated with lower iron status, lower ferritin status, higher transferrin status or lower transferrin saturation status with p<5.10−8.
†Per risk allele effect estimates are reported for SNPs, per SD increase effect estimates are reported for scores.
‡T is the risk allele for iron (associated with lower iron status) and G is the risk allele for transferrin and transferrin saturation (associated with 
higher transferrin status and lower transferrin saturation status).
ALSPAC, Avon Longitudinal Study of Parents and Children; SNP, single nucleotide polymorphism. 
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Table 3 Associations of maternal genotypes and genotypic risk scores with haemoglobin concentrations in late pregnancy 
stratified by iron supplementation in late pregnancy
SNPs Risk allele*
Unsupplemented women (n=3055) Supplemented women (n=2248)
β† (95% CI) P trend β† (95% CI) P trend
rs1799945 C −0.12 (−0.19 to –0.06) 1.3×10−4 −0.04 (−0.12 to 0.04) 0.31
rs1800562 G −0.22 (−0.30 to –0.13) 7.3×10−7 −0.14 (−0.25 to –0.03) 0.01
rs855791 A −0.09 (−0.14 to –0.05) 8.6×10−5 −0.14 (−0.19 to –0.09) 2.0×10−7
rs8177240 T/G‡ −0.04 (−0.09 to 0.01) 0.12 −0.01 (−0.06 to 0.05) 0.81
rs7385804 C 0.00 (−0.05 to 0.05) 0.95 0.00 (−0.05 to 0.06) 0.86
rs744653 T −0.04 (−0.11 to 0.02) 0.18 0.06 (−0.02 to 0.13) 0.14
rs651007 T −0.05 (−0.11 to 0.01) 0.08 −0.04 (−0.10 to 0.03) 0.27
rs411988 A −0.02 (−0.06 to 0.03) 0.46 0.02 (−0.04 to 0.07) 0.54
rs9990333 C 0.04 (0.00 to 0.09) 0.07 −0.05 (−0.10 to 0.00) 0.06
rs4921915 A −0.02 (−0.07 to 0.04) 0.55 0.00 (−0.07 to 0.06) 0.91
rs6486121 C 0.00 (−0.04 to 0.05) 0.86 0.02 (−0.03 to 0.08) 0.40
rs174577 A −0.01 (−0.05 to 0.04) 0.76 −0.02 (−0.08 to 0.03) 0.41
Iron score −0.12 (−0.15 to –0.09) 7.5×10−13 −0.09 (−0.13 to –0.05) 4.4×10−6
Ferritin score −0.11 (−0.15 to –0.08) 2.0×10−12 −0.06 (−0.09 to –0.02) 4.5×10−3
Transferrin score −0.04 (−0.07 to –0.01) 0.01 −0.04 (−0.07 to 0.00) 0.06
Transferrin saturation score −0.11 (−0.14 to –0.07) 8.1×10−11 −0.08 (−0.12 to –0.04) 2.8×10−5
*Associated with lower iron status, lower ferritin status, higher transferrin status or lower transferrin saturation status with p<5.10−8.
†Per risk allele effect estimates are reported for SNPs, per SD increase effect estimates are reported for scores.
‡T is the risk allele for iron (associated with lower iron status) and G is the risk allele for transferrin and transferrin saturation (associated with 
higher transferrin status and lower transferrin saturation status).
SNP, single nucleotide polymorphism. 
Table 4 Associations between maternal genotypic scores and atopy, asthma, FEV1, FVC and FEF25-75 in the offspring
OR or β*† (95% CI)
Iron score Ferritin score Transferrin score
Transferrin saturation 
score
Atopy (n=3943)
  Per SD increase 1.02 (0.95 to 1.10) 1.00 (0.92 to 1.08) 0.97 (0.90 to 1.04) 1.00 (0.93 to 1.08)
  P for trend 0.60 0.93 0.38 0.96
Asthma (n=4873)
  Per SD increase 1.05 (0.96 to 1.14) 0.97 (0.89 to 1.06) 0.97 (0.89 to 1.05) 1.03 (0.94 to 1.12)
  P for trend 0.31 0.54 0.47 0.56
FEV1 (n=4014)
  Per SD increase −0.02 (−0.05 to 0.01) −0.01 (−0.04 to 0.02) −0.01 (−0.05 to 0.02) −0.02 (−0.05 to 0.01)
  P for trend 0.26 0.48 0.34 0.14
FVC (n=4086)
  Per SD increase 0.00 (−0.03 to 0.03) 0.01 (−0.03 to 0.04) −0.01 (−0.04 to 0.02) −0.01 (−0.04 to 0.02)
  P for trend 0.79 0.75 0.42 0.44
FEF25-75 (n=4086)
  Per SD increase −0.02 (−0.05 to 0.01) −0.02 (−0.06 to 0.01) −0.02 (−0.05 to 0.01) −0.02 (−0.06 to 0.01)
  P for trend 0.19 0.13 0.27 0.13
*OR for asthma and atopy; difference in age, height and gender-adjusted SD units (β) for FEV1, FVC and FEF25-75.
†Adjusted for iron supplementation during pregnancy and population substructure.
FEF25-75, maximal mid-expiratory flow; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity. 
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results showed that, while collider bias did lead to inflated 
type 1 error rates, false positive rates were only substan-
tially greater than nominal levels when the effect of iron 
levels on supplementation was extreme. For realistic 
values of this parameter, inflation of type 1 error rates was 
not substantial (see online supplementary file). When we 
studied the associations between the child’s genotypic 
scores and child’s outcomes, no association was found 
with childhood FEV1 or FVC. However, positive associa-
tions were found between the child’s iron and transferrin 
saturation scores and childhood atopy, and between the 
child’s ferritin score and childhood FEF25-75 (see online 
supplementary table 5). When we conducted MR-Egger 
and weighted median analyses to assess the associa-
tions between the maternal transferrin saturation score 
and childhood FEV1 and FVC among unsupplemented 
mothers, similar point estimates to the ones obtained 
using standard inverse variance weighted approach were 
found, suggesting no evidence of pleiotropy (online 
supplementary figures 4 and 5 for FEV1 and FVC, respec-
tively). Weighted median analysis also suggested evidence 
for a statistically significant slope (p=0.05 and 0.03 for 
FEV1 and FVC, respectively).
dIscussIon
Using an MR approach, we found weak evidence that 
a lower maternal iron status during pregnancy was 
associated with lower FEV1 and FVC in the offspring. 
These associations were only apparent in the absence of 
iron supplementation in late pregnancy. These results 
are in keeping with recent findings in ALSPAC in which 
we have found that lower maternal haemoglobin concen-
trations and anaemia in later pregnancy were associ-
ated with lower childhood lung function.12 They are 
also consistent with limited evidence from the SEATON 
study, suggesting that low prenatal iron status was associ-
ated with lower FEV1, although in that study the associa-
tion was with ferritin in early pregnancy.10 In our study, 
statistical power was greater for analysis of lung func-
tion, a continuous outcome, than for analyses of binary 
outcomes.
A plausible mechanism for the associations we 
observed between the maternal genotypic scores and 
childhood lung function, and especially FEV1, could be 
that prenatal iron status influences growth and devel-
opment of fetal lungs, especially airways. In support of 
this hypothesis, animal experiments have suggested that 
an adequate supply of iron is needed for optimal airway 
development. Chelation of iron by desferrioxamine in ex 
vivo lung buds from mouse embryos reduced the vascular 
network surrounding the developing lung buds and 
reduced epithelial branching; these inhibitory effects on 
vascular growth and epithelial branching were reversed 
by administering iron.32
Table 5 Associations between maternal genotypic scores and atopy, asthma, FEV1, FVC and FEF25-75 in the offspring of 
women without iron supplementation in late pregnancy
OR or β*† (95% CI)
Iron score Ferritin score Transferrin score
Transferrin saturation 
score
Atopy (n=2208)
  Per SD increase 1.08 (0.97 to 1.19) 1.06 (0.95 to 1.17) 0.97 (0.88 to 1.07) 1.05 (0.95 to 1.17)
  P for trend 0.15 0.28 0.56 0.31
Asthma (n=2787)
  Per SD increase 1.09 (0.97 to 1.22) 0.98 (0.88 to 1.10) 1.00 (0.90 to 1.12) 1.08 (0.96 to 1.21)
  P for trend 0.15 0.75 0.95 0.20
FEV1 (n=2300)
  Per SD increase −0.04 (−0.08 to 0.00) −0.02 (−0.06 to 0.02) −0.03 (−0.07 to 
0.01)
−0.05 (−0.09 to −0.01)
  P for trend 0.07 0.38 0.13 0.03
FVC (n=2336)
  Per SD increase −0.03 (−0.07 to 0.01) −0.01 (−0.05 to 0.03) −0.03 (−0.07 to 
0.01)
−0.04 (−0.08 to 0.00)
  P for trend 0.12 0.72 0.14 0.04
FEF25-75 (n=2336)
  Per SD increase −0.02 (−0.06 to 0.02) −0.02 (−0.06 to 0.02) −0.02 (−0.06 to 
0.02)
−0.02 (−0.06 to 0.02)
  P for trend 0.35 0.39 0.36 0.28
*OR for asthma and atopy; difference in age, height and gender-adjusted SD units (β) for FEV1, FVC and FEF25-75.
†Adjusted for population substructure.
FEF25-75, maximal mid-expiratory flow; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity. 
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strengths and limitations
One major strength of the ALSPAC birth cohort, apart 
from its size, population-based prospective design, rich 
information on numerous lifestyle factors and detailed 
phenotypic outcome measurements, is that maternal 
DNA was collected, enabling maternal genotyping and 
an MR approach; many birth cohort studies have not 
collected maternal DNA. To date, few studies have used 
an MR approach to investigate the role of prenatal nutri-
tion in the aetiology of respiratory and atopic disorders 
in childhood, although two such studies have been 
conducted in ALSPAC.33 34 A limitation of using MR in 
our study is that, despite ALSPAC’s size, analyses may have 
been underpowered to detect small or modest effects, 
although we used genotypic scores to increase statistical 
power.26 The SNPs used to derive the maternal genotypic 
scores were selected from the largest GWA meta-anal-
ysis conducted so far on iron and iron biomarkers.24 
Although the size and power of this GWA meta-analysis 
ensure that those SNPs are valid predictors of iron status 
in the general population, we cannot be sure that they 
are valid predictors of maternal iron status in pregnancy. 
Another limitation is that no iron biomarker had been 
measured in ALSPAC mothers during pregnancy to 
confirm directly that the genetic risk scores were valid IVs. 
Nevertheless, using maternal haemoglobin as a proxy for 
prenatal iron status, we showed that three key SNPs, and 
all four maternal genotypic scores, were strongly associ-
ated with haemoglobin concentrations in ALSPAC. We 
believe that this provides partial ‘internal validation’ of 
these genetic instruments as predictors of maternal iron 
status in pregnancy in the ALSPAC population. The fact 
that maternal genotypic scores were strongly associated 
with iron supplementation in late pregnancy, in a dose–
response manner, provides further validation (those 
with the highest scores being most likely to develop iron 
deficiency anaemia, and hence to be given iron supple-
ments, especially in late pregnancy when fetal demands 
are higher and anaemia is more common). It is worth 
emphasising that, despite supplementation, we still saw 
associations between all genetic instruments and haemo-
globin concentrations among women. However, those 
associations were stronger among unsupplemented 
women, which is not surprising, as we would expect 
stronger genetic associations with iron biomarkers in 
the absence of iron supplementation. The fact that we 
also observed stronger associations between genotypic 
scores and lung function in children of unsupplemented 
mothers would support a causal interpretation. A major 
strength of using an MR approach is that the associations 
between the genetic instruments and outcomes should 
not be confounded. We confirmed that (with the excep-
tion of iron supplementation, occurring as a consequence 
of iron deficiency) the genotypic scores were not associ-
ated with a wide range of maternal and offspring charac-
teristics, suggesting that our findings for lung function 
were unlikely to be confounded by lifestyle factors. The 
use of MR in the specific situation of testing maternal 
intrauterine effects on postnatal offspring outcomes, 
when there might be an overlap between maternal and 
offspring genetic variants, may lead to the violation of the 
exclusion restriction assumption of IV analyses. Several 
approaches have been proposed to address this issue.31 
When we studied the associations between the child’s 
genotypic scores and childhood outcomes, no associa-
tion was found with childhood FEV1 or FVC, suggesting 
that the associations that were found between the 
maternal genotypic scores and childhood FEV1 or FVC 
among unsupplemented mothers were not confounded 
by the child’s genetic variants. When we used MR-Egger 
and weighted median analyses, no evidence of pleiot-
ropy was found and results supported a causal interpre-
tation of the associations found between the maternal 
transferrin saturation score and childhood FEV1 and 
FVC among unsupplemented mothers. Nevertheless, we 
cannot totally rule out the possibility that there may be 
some residual pleiotropy and that the genetic associa-
tions might be confounded. Restriction of our analyses 
to white mothers, and adjustment for genetic markers 
derived by PCA, ensured that our findings were unlikely 
to be confounded by population substructure. Finally, 
the simulation study showed that it is unlikely that the 
results of this paper were driven by collider bias alone.
While there are multiple blood biomarkers of maternal 
iron status aside from iron, such as plasma ferritin, trans-
ferrin (iron is distributed systemically in the circulation 
as transferrin), transferrin saturation, or serum soluble 
transferrin receptor and its ratio to ferritin, no single 
marker of iron metabolism is considered ideal for assess-
ment of iron deficiency, as each has limitations in terms 
of sensitivity and specificity.35 For example, serum iron 
is an unreliable indicator of availability of iron to the 
tissues because of wide fluctuation in levels due to recent 
ingestion of Fe, diurnal rhythm and other factors, such 
as infection.36 Transferrin saturation (ie, serum iron/
total iron binding capacity×100%) is a more sensitive 
and specific indicator of iron deficiency than serum iron 
alone.35 However, it also fluctuates due to a diurnal vari-
ation in serum iron and is affected by the nutritional 
status. Serum ferritin is a stable glycoprotein that accu-
rately reflects iron stores in the absence of inflamma-
tory change and it is the first laboratory test to become 
abnormal as iron stores decrease and it is not affected 
by recent iron ingestion.36 However, serum ferritin is 
thought to be of limited usefulness in pregnancy because 
concentrations fall late in pregnancy, even when bone 
marrow iron is present37; this might partly explain why 
no association was seen between the genotypic ferritin 
score and lung function in our study. Another limitation 
of ferritin is that it is an acute phase reactant and concen-
trations will rise when there is active infection or inflam-
mation.38 We therefore decided to derive four genotypic 
scores, predictive of four different iron biomarkers, to be 
able to assess prenatal iron status as comprehensively as 
possible. However, we cannot exclude the possibility that 
our findings for FEV1 and FVC occurred by chance, given 
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the p values and the multiple analyses carried out; hence 
they should be interpreted with caution. Given the a 
priori nature of the hypothesis being tested, and the fact 
that some outcomes of interest are highly correlated, it 
did not seem appropriate to correct for multiple testing.
conclusIons
Using an MR approach we have found weak evidence 
suggesting that low maternal iron status during preg-
nancy may cause impaired childhood lung function. 
There is need for further studies to strengthen causal 
inference. One way could be to conduct larger MR studies 
across multiple cohorts (if maternal genotype data are 
available), thus increasing statistical power. Another way 
could be to follow-up the offspring of mothers who have 
taken part in previous trials of iron supplementation in 
pregnancy, and to measure their lung function.39
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